Show simple item record

dc.contributor.authorCheng, Xiao-Dong
dc.contributor.authorYuan, Quan
dc.contributor.authorYue, Qiao-Hong
dc.contributor.authorZheng, Qing-Bing
dc.contributor.authorMa, Yue-Yun
dc.contributor.authorYang, Bing-Chun
dc.contributor.authorZhang, Rong
dc.contributor.authorChen, Yi-Xin
dc.contributor.authorSu, Ming-Quan
dc.contributor.authorZhang, Jun
dc.contributor.author张军
dc.contributor.authorXia, Ning-Shao
dc.contributor.author夏宁邵
dc.contributor.authorHao, Xiao-Ke
dc.date.accessioned2012-03-15T08:32:19Z
dc.date.available2012-03-15T08:32:19Z
dc.date.issued2010-11-03
dc.identifier.citationJournal of Clinical Virology.2011,Vol.50 Issue(2):153-155zh_CN
dc.identifier.issn1386-6532
dc.identifier.uriWOS:000286590600013
dc.identifier.urihttp://dx.doi.org/doi:10.1016/j.jcv.2010.10.002
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/11760
dc.description.abstractBackground: Rapid influenza A diagnostic tests (RIDTs) play an important role in the clinical setting, especially in the influenza post-pandemic era with three influenza A viruses in circulation. Objectives: Determine the sensitivity and specificity of a new RIDT (FluA Dot) by comparison with BD Directigen EZ FluA+B and CDC rRT-PCR. Study design: Two sets of experiments were conducted to determine the performance of the new test. (1) Serial dilutions of eight pandemic (H1N1) 2009 (pH1N1) isolates, five seasonal H3N2 isolates, five seasonal H1N1 isolates and three recombinant nucleoproteins were tested by FluA Dot assay, Directigen EZ FluA+B test and CDC real-time RT-PCR. (2) Using CDC rRT-PCR as the gold standard, the clinical sensitivity and specificity of the FluA Dot and Directigen EZ FluA+B were evaluated in nasopharyngeal swab (NPS) specimens of 807 patients presenting with influenza-like illness. Results: The average analytical sensitivity of FluA Dot (0.06 ng/mL for recombinant nucleoproteins and 2.16 +/- 0.85 log 10 TCID(50) for viruses) was approximately 10-fold higher than Directigen EZ FluA+B (1-2 ng/mL for recombinant nucleoproteins and 3.54 +/- 0.81 log 10 TCID(50) for viruses), and was approximately 10-fold lower than the CDC rRT-PCR (1.09 +/- 0.69 log 10 TCID(50) for viruses). Among 807 NPS specimens tested, the sensitivities and specificities of FluA Dot were 91.1% (95% CI: 86.7-94.4%)/99.7% (95% CI: 98.7-99.9%), and the Directigen EZ FluA+B were 71.9% (95% CI: 65.7-77.6%)/99.8%(95% CI: 99.0-99.9%). Conclusion: The new test (FluA Dot) exhibit higher sensitivity than Directigen EZ FluA+B both in pH1N1 and seasonal influenza A detection. The promising RIDT can play important roles in influenza diagnosis and therapy. (C) 2010 Elsevier B.V. All rights reserved.zh_CN
dc.description.sponsorshipKey special subjects of Infectious diseases[2008ZX10004-006]; Key project of Science & Technology of Fujian province[2008Y0059]; National High Technology Researchand Development Program[2010AA022801]zh_CN
dc.language.isoenzh_CN
dc.publisherELSEVIER SCIENCE BVzh_CN
dc.subjectPandemic (H1N1) 2009zh_CN
dc.subjectInfluenza A viruszh_CN
dc.subjectRapid influenza diagnostic test (RIDT)zh_CN
dc.subjectFluA Dotzh_CN
dc.titleEvaluation of a new rapid influenza A diagnostic test for detection of pandemic (H1N1) 2009 and seasonal influenza A viruszh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record